PUBLIC RELEASE DATE: <\/p>\n
28-Apr-2014 <\/p>\n
Contact: Franca Davenport f.davenport@imperial.ac.uk<\/a> 020-759-42198 Imperial College London<\/p>\n New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data. <\/p>\n Researchers from Imperial College London conducted a meta-analysis of 49 randomised controlled trials of bone marrow stem cell therapy for heart disease. The study, published today in the British Medical Journal, identified and listed over 600 discrepancies within the trial reports. <\/p>\n Discrepancies were defined as two (or more) reported facts that could not both be accurate because they were logically or mathematically incompatible. For example, one trial reported that it involved 70 patients, who were divided into two groups of 35 and 80. <\/p>\n The researchers found eight trials that each contained over 20 discrepancies. <\/p>\n The researchers found that the discrepancy count in a trial was the most important determinant of the improvement in cardiac function reported by that trial. Trials with fewer and fewer discrepancies showed progressively smaller improvements in cardiac function. The five trials with no discrepancies at all showed an effect size of zero (see bar chart in Notes to Editors). <\/p>\n Previous meta-analyses looking at the results of lots of clinical trials have suggested that on average, bone marrow stem cell therapy has a significant positive effect on improving heart function. However, some trials have shown that it successfully improves heart function whilst others have not. The reasons for this are unclear. <\/p>\n Professor Darrel Francis, one of the study authors from the National Heart and Lung Institute at Imperial College London, said: \"Clinical trials involve a huge amount of data and so it is understandable that discrepancies sometimes arise when researchers are presenting their findings. However, our study suggests that these discrepancies can have a significant impact on the overall results. It is a powerful reminder to all of us conducting clinical trials to be careful and vigilant to avoid discrepancies appearing in the work. <\/p>\n <\/p>\n Continued here: <\/p>\n Study of stem cell trials links discrepancies in data with reported success of treatment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" PUBLIC RELEASE DATE: 28-Apr-2014 Contact: Franca Davenport f.davenport@imperial.ac.uk<\/a> 020-759-42198 Imperial College London New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data. Continue reading